Our Insights Oncology Anthony Iannacci 9/15/26 Oncology Anthony Iannacci 9/15/26 BMS gains approval for first ever CELMoD, Zenbexus, in relapsed/refractory multiple myeloma and appears poised for the approval of one more Read More Oncology Anthony Iannacci 10/3/22 Oncology Anthony Iannacci 10/3/22 CAR-T Outlook Read More Want to get in touch? Click here
Oncology Anthony Iannacci 9/15/26 Oncology Anthony Iannacci 9/15/26 BMS gains approval for first ever CELMoD, Zenbexus, in relapsed/refractory multiple myeloma and appears poised for the approval of one more Read More
